New hope for advanced cancer patients: BC2027 enters early human testing
Disease control
Recruiting now
This early-phase study tests a new drug called BC2027 in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be in fairly good …
Phase: PHASE1 • Sponsor: Biocity Biopharmaceutics Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC